CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.29 – $4.10
Volume4,638
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.09M
Price / earnings
—
Price / book
0.28×
Price / sales
—
EV / sales
—
EV / EBITDA
0.88×
Profitability
Earnings per share
-$11.43
Return on assets
-76.12%
Return on equity
-91.75%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.86×
Quick ratio
5.86×
Cash ratio
5.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CNSP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.5M
$1.43M
$2.82M
$1.06M
$1.24M
$1.09M
$1.7M
$1.38M
Research and development
$1.2M
$3.54M
$3.17M
$2.2M
$1.17M
$3.24M
$1.5M
$4.24M
Total operating expenses
$2.7M
$4.98M
$5.99M
$3.25M
$2.41M
$4.34M
$3.2M
$5.63M
Operating income
-$2.7M
-$4.98M
-$5.99M
-$3.25M
-$2.41M
-$4.34M
-$3.2M
-$5.63M
Interest expense
-$4K
-$6.11K
-$2.72K
-$2.12K
-$4K
-$6.21K
-$2.77K
-$2.26K
Income before taxes
-$2.59M
-$4.94M
-$5.96M
-$3.22M
-$2.38M
-$4.3M
-$3.18M
-$5.61M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.59M
-$4.94M
-$5.96M
-$3.22M
-$2.38M
-$4.3M
-$3.18M
-$5.61M
Net income attributable to common shareholders
-$2.59M
-$4.94M
-$5.96M
-$3.22M
-$2.38M
-$4.3M
-$3.18M
-$5.61M
EBITDA
-$2.69M
-$4.97M
-$5.99M
-$3.25M
-$2.41M
-$4.34M
-$3.2M
-$5.63M
Basic earnings per share
-$0.38
-$7.30
-$9.65
-$5.76
-$6.42
-$18.93
-$35.38
-$153.20
Diluted earnings per share
-$0.38
-$7.30
-$9.65
-$5.76
-$6.42
-$18.93
-$35.38
-$153.20
Recent news
Company coverage with links to the original publishers.
The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.
CNS Pharmaceuticals, a biopharmaceutical company, is developing novel treatments for brain and central nervous system cancers. The company's lead drug candidate, Berubicin, is in a late-stage pivotal trial, and it has recently in-licensed another promising drug, TPI-287, for glioblastoma treatment.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.
BIOLASE, Inc. (NASDAQ: BIOL)
On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales guidance below estimates.
UPS reported a fourth-quarter fiscal 2023 revenue decline of 7.8% year-over-year to $24.92 billion, missing the consensus of $25.43 billion. Adjusted EPS was $2.47, down from $3.62 in Q4 2022, in line with the consensus.
United Parcel Service shares dipped 8.3% to $145.04 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers
Agape ATP Corporation (NASDAQ: ATPC) shares jumped 79% to $0.9120.
Pixelworks, Inc. (NASDAQ: PXLW) rose 56.8% to $2.3209 after the company entered into a multi-year agreement with Walt Disney Studios.
Agrify Corporation (NASDAQ: AGFY) surged 50.7% to $0.9120 after a 13D filing showed I-Tseng Jenny Chan reported a 49.99% stake in the company.
Rail Vision Ltd. (NASDAQ: RVSN) gained 38.8% to $20.38 after the company announced its next generation AI-based computer to be incorporated in its Main Line and Switch Yard systems.
Inspire Veterinary Partners, Inc. (NASDAQ: IVP) climbed 38% to $0.2359 after falling around 24% on Monday. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering.
Sanmina Corporation (NASDAQ: SANM) shares climbed 36.7% to $69.21 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.
Selina Hospitality PLC (NASDAQ: SLNA) gained 20.8% to $0.4603.
C3is Inc. (NASDAQ: CISS) shares surged 19.1% to $0.1609 after a 13G filing showed S.H.N. Financial reported a 9.1% stake in the company.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) rose 18.2% to $0.39.
Kura Oncology, Inc. (NASDAQ: KURA) climbed 16.1% to $21.60. Kura Oncology reported preliminary ziftomenib combination data in acute myeloid leukemia.
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 13.9% to $1.56 after gaining more than 25% on ...
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter.
Super Micro Computer reported quarterly earnings of $5.59 per share, beating the analyst consensus estimate of $4.93. The company reported quarterly sales of $3.67 billion, which topped the analyst consensus estimate of $3.06 billion.
The company also raised its fiscal year 2024 guidance for revenues from a range of $10 billion to $11 billion to a range of $14.3 billion to $14.7 billion.
Super Micro Computer shares jumped 10.6% to $548.25 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Agape ATP Corporation (NASDAQ: ATPC) gained 65.1% to $0.8420 in pre-market trading after gaining around 13% on Monday.
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 45.3% to $1.99 in pre-market trading after gaining more than 25% on Monday. Petros Pharmaceuticals recently announced completion of initial cohort of Phase 2 equivalent self-selection study.
C3is Inc. (NASDAQ: CISS) shares jumped 40.6% to $0.19 in pre-market trading after a 13G filing showed ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.